<DOC>
	<DOCNO>NCT00697840</DOCNO>
	<brief_summary>The purpose present trial ass safety , reactogenicity immunogenicity adjuvanted hepatitis B vaccine , Engerix™-B hepatitis B vaccine new formulation administer 0 , 6 month</brief_summary>
	<brief_title>Safety , Immunogenicity Reactogenicity Recombinant Hepatitis B Vaccine ( Adjuvanted &amp; New Formulation ) Engerix™-B</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 18 40 year old . Written inform consent obtain subject . Good physical condition establish physical examination history take time entry . Female participant avoid become pregnant study period contraceptive program least 2 month entry Pregnancy lactation . Positive titre anti HBs antibody . Any vaccination hepatitis B past . Any previous administration MPL . Elevated serum liver enzymes . History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Axillary temperature &gt; 37.5°C time injection . Any acute disease moment entry . Chronic alcohol consumption . Any treatment immunosuppressive immunostimulant therapy . Any chronic drug treatment , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Simultaneous administration vaccine ( ) . Administration immunoglobulin study period . Simultaneous participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Engerix™-B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>